Search results

More info coming soon! More info on the NARILIS website

Thematic sessionsThe day will be organized in two thematic sessions:Cancer metabolismNew advances in cancer therapyInvited speakersProf. Rebecca FITZGERALD, Early Cancer Institute, University of Cambridge, UKDr. Sébastien DUTERTRE, IBMM, University of Montpellier, FranceProf. Sarah-Maria FENDT, Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven, BelgiumDr. Arnaud BLOMME, Laboratory of Metabolic Regulation, GIGA Institute, University of Liège, Belgium Call for communicationsYoung researchers are invited to submit abstracts for oral communications and posters. All topics related to the field of cancer research are welcome. The deadline for abstract submission is April 1, 2025. Organizing committeeProf. Jean-Pierre Gillet - UNamur, NARILIS, Laboratory of Molecular Cancer BiologyProf. Marc Hennequart - UNamur, NARILIS, Laboratory of Cancer metabolismProf. Marielle Boonen - UNamur, NARILIS, Laboratory of Intracellular Trafficking BiologyProf. Benjamin Beck - ULB, IRIBHMProf. Lionel D'Hondt - CHU UCL Namur, Department of Oncology More info

Target audienceGeneral practitioners (in practice or in training)PharmacistsMedical and pharmacy studentsObjectivesShare and discuss scientific articles relevant to frontline practice in a friendly and caring atmosphereStrengthen skills in critical reading and evidence-based medicineCreate a lasting link between the field and the academic worldFederate an active and committed medico-pharmaceutical community.pharmaceutical communityWhy participate?Because science moves fast, and we all benefit from taking the time to read, understand, and question the literature together. Because quality care starts with shared reflection. And because it's the ideal opportunity to strengthen bridges between disciplines.Location and frequency of meetingsUNamur - Quai22 - 2 times a yearFirst meeting: 5/06/2025 (free with registration)INAMI accreditation required. I want to register

The program 2:00 pm | Keynote lecture on the use of AI in research - Hugues BERSINI, Professor at the Université libre de Bruxelles: "Can science be just data driven?" 3:00 pm | Presentations by UNamur researchers3:00 pm | Catherine Guirkinger: Use of AI in an economic history project3:15 pm | Nicolas Roy (PI: Alexandre Mayer): AI at the service of innovation in photonics and optics: revealing the secrets of scrolls through the classification of animal species15:25 | Nemanja Antonic (PI: Elio Tuci): An in silico representation of C. elegans collective behaviour<15h35 | Nicolas Franco : The benefits and dangers of "predicting the future" with covid-like machine learning models 15h45 | Michel Ajzen : Managerial and human implications of AI in organizations <15h55 | Robin Ghyselinck (PI : Bruno Dumas) : Deep Learning for endoscopy: towards next generation computer-aided diagnosis4:05 pm | Auguste Debroise (PI : Guilhem Cassan) : LLMs to measure the importance of stereotypes within gender representations in Hollywood films16h15 | Gabriel Dias De Carvalho : Learning practices in physics using generative AI16h25 | Sébastien Dujardin (PI : Catherine Linard) : Where Geography meets AI: A case study on mapping online flood conversations16h35 | Jeremy Dodeigne : LLMs in SHS: revolutionary tools in a Wild West Territory? Reflections on costs, transparency and open science16h45 | Antoinette Rouvroy : Governing AI in Democracy17h00 | Keynote lecture on ethics and guidelines to consider when using AI in research projects and writing research articles - Bettina BERENDT, Professor at KU Leuven18h00 | Benoît Frenay and Michaël Lobet : Creation of an IA scientific committee at UNamur18:10 | DrinkA certificate of attendance, worth 0.5 cross-disciplinary doctoral training credits, will be issued on request. Contact: secretariat.adre@unamur.beThis event is free of charge, but registration is required. I want to register

Program Overview This event will take place over two exciting days, featuring a diverse program designed to offer a dynamic and interactive experience for all participants. The entire symposium will be conducted in English.On Wednesday, December 9, and Thursday, December 10, two days of scientific and technical sessions will be dedicated to the topics of alternative proteins, the microbiome, and functional ingredients.On Wednesday, December 9, there will be a public lecture (in English) presented by Dr. Patrice Cani on the topic “Nourishing Your Gut: Nutrition, Microbiota, and Health.”For experienced researchers and group leaders, we are organizing a third day on December 11 dedicated to international collaboration, including laboratory visits and a workshop focused on establishing structured collaborative projects. Separate registration is requiredOverview of the ThemesThis symposium is structured around the three projects in the FoodWal portfolio, while pushing their boundaries and framing them within a “One Health” approach.The session titled “Building Sustainable Value Chains for Alternative Proteins: from protein sources to the development of healthy food products” will provide an opportunity to present scientific and technological advances in the creation and characterization of alternative protein sources and products, as well as socioeconomic perspectives on the development, maintenance, and growth of sustainable value chains for alternative proteins.The session titled “Research on the Microbiome and Microbiotics: Innovation in Nutrition for Better Health” will present scientific advances in the characterization, understanding, and modulation of the microbiome, as well as cutting-edge technologies aimed at developing innovative microbiotics.Finally, the session titled “Functional Ingredients and Bioactive Compounds: Food Science and Biotechnology for Health” will focus on scientific advances in the identification, characterization, and understanding of the mechanisms of action of functional ingredients, as well as cutting-edge technologies designed to develop and produce innovative functional ingredients. More information on the FoodWal website Je m'inscris

JuryProf. Steve LANNERS (UNamur), ChairProf. Johan WOUTERS (UNamur), SecretaryProf. Pierre FRANCOTTE (ULiège)Dr. Marie HAUFROID (UCB)Prof. Lionel POCHET (UNamur)AbstractCurrently, Mycobacterium tuberculosis remains the second deadliest infectious agent in the world, responsible for 1.6 million deaths in 2021. The burden and cost of current treatment (6 months and 4,000 euros), coupled with the alarming emergence of antibiotic-resistant strains, underscore the absolute urgency of developing new therapeutic molecules. This study focuses on the Mycobacterium tuberculosis phosphoserine phosphatase (MtSerB2), an enzyme essential for serine biosynthesis and vital to the pathogen’s survival. Furthermore, this protein plays a key role in host invasion (through its interactions with the NF-κB factor and the cellular cytoskeleton), making MtSerB2 a prime therapeutic target for the development of new, potent anti-tuberculosis drugs.One of the innovative strategies explored in this thesis is based on destabilizing the protein’s structure (disruption of protein structure). The goal is to design a molecule capable of disrupting the enzyme’s conformation, thereby causing it to lose its catalytic activity. This new class of molecules is expected to exhibit significantly higher selectivity for MtSerB2 compared to its human homolog, human phosphoserine phosphatase (hPSP).To this end, the Mycobacterium avium phosphoserine phosphatase (MaSerB) was initially used as a model system, justified by its 83% sequence identity with MtSerB2 and its propensity to crystallize rapidly. Initially, a virtual screening of drugs already available on the market was conducted to identify potential inhibitors of MaSerB. Enzymatic assays based on malachite green detectionwere then performed to evaluate the inhibitory activity of the various candidates. The results demonstrated increased selectivity of these compounds for dimeric proteins (MtSerB2 and MaSerB) compared to the human enzyme hPSP.Notably, subsequent enzymatic assays conducted directly on MtSerB2 revealed response profiles that differed from those observed with the MaSerB model. To elucidate the molecular basis of these differences, the structure of the protein in its ligand-bound state is currently being investigated. To this end, protein-inhibitor complexes have been crystallized and will be analyzed by X-ray diffraction.